The Latest Cardiac and Vascular News
PARIS, April 28, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products that act directly on the brain in order to address difficult-to-treat/resistant hypertension and heart failure, today reported its full year 2021 results. […]
− Achieved First Quarter 2022 Global Net Product Revenues of $187 Million for ONPATTRO®, GIVLAARI®, and OXLUMO® – − Reported Positive 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in hATTR Amyloidosis Patients with Polyneuropathy – − Announced 3-Month Extension of Review Period for New Drug Application for Vutrisiran due […]
First-quarter revenue of $3.7 billion increased 26% on a reported basis, 29% on a constant currency basis and 3% on an operational basis1 First-quarter U.S. GAAP earnings per share (EPS) totaled $0.14; Adjusted EPS totaled $0.93 Baxter expects full-year 2022 sales growth of 23% to 24% on a reported basis, […]
FY 2022 Annual Revenue of $1.032 billion, Up 22% Versus Prior Year DANVERS, Mass.–(BUSINESS WIRE)–ABIOMED, Inc. (NASDAQ: ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 2022. Financial summary and operational highlights: Revenue for the […]
MARLBOROUGH, Mass., April 27, 2022 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis and 9.7 percent on an organic2 basis, all compared to the prior year period. The company reported GAAP net income […]
IRVINE, Calif., April 26, 2022 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2022. First Quarter Highlights and Outlook Q1 sales grew 10 percent to $1.34 billion; underlying1 13 percent Q1 TAVR sales grew 11 percent; underlying 14 percent Q1 EPS was $0.59; adjusted1 EPS was $0.60 Full year 2022 financial […]
Series A funding round will accelerate international expansion and fuel AI-based medical algorithm development. CAMBRIDGE, Mass., April 27, 2022 /PRNewswire/ — IMPLICITY®, a leader in remote patient monitoring and cardiac data management solutions, today announced it has raised $23 million in Series A funding led by new investors: Crédit Mutuel Innovation and Bpifrance. Additional investors […]
STOCKHOLM, April 27, 2022 /PRNewswire/ — A strong start for the year with continued overall growth Our strong finish of 2021 is now followed by a first quarter of 2022 with considerable growth for both order intake and net sales. We increased the order book to 91.4 (72.9) MSEK compared to the end […]
Quantum Genomics has equipped itself with new financial means to pursue the development of firibastat and explore new therapeutic fields based on the patented technology platform built around BAPAIs Quantum Genomics is taking this opportunity to strengthen and expand its shareholder structure PARIS, April 27, 2022 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth […]
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2022 second quarter ended March 31, 2022 and updated its financial outlook for its fiscal 2022. Summary of Second Quarter and Recent […]
